Allergologie select最新文献

{"title":"Does the teicoplanin skin test predict IgE-mediated hypersensitivity?","authors":"Nur Betül Baştuğ İnan, Özge Göktürk, Yavuz Karahan, Kurtuluş Aksu","doi":"10.5414/ALX02632E","DOIUrl":"10.5414/ALX02632E","url":null,"abstract":"<p><p>Various delayed-type hypersensitivity reactions have been reported following teicoplanin administration, including drug rash with eosinophilia and systemic symptoms (DRESS syndrome), and acute generalized exanthematous pustulosis (AGEP). Until recently, IgE-mediated hypersensitivity reactions to teicoplanin were considered to be rare. However, reports of such reactions have increased in recent years. These case reports also suggest that teicoplanin skin testing can predict IgE-mediated hypersensitivity reactions. In the present case, teicoplanin skin prick and intradermal tests were negative, yet an immediate skin reaction occurred during provocation.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"10 ","pages":"98-100"},"PeriodicalIF":5.1,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13202710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148045337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert consensus on the long-term use of lanadelumab in hereditary angioedema: Toward harmonized care.","authors":"Emel Aygören-Pürsün, Jens Greve, Inmaculada Martinez-Saguer, Susanne Trainotti, Mathias Sulk, Bettina Wedi, Ellen Witte-Händel, Markus Magerl","doi":"10.5414/ALX02622E","DOIUrl":"10.5414/ALX02622E","url":null,"abstract":"<p><strong>Background: </strong>Hereditary angioedema (HAE) is a rare, potentially life-threatening disease caused in most cases by C1 inhibitor deficiency. Lanadelumab, a monoclonal antibody targeting plasma kallikrein, is an effective long-term prophylactic (LTP) treatment for HAE. However, consensus on best practices remains lacking.</p><p><strong>Objectives: </strong>This study aimed to report consensus statements on key principles on long-term lanadelumab therapy for HAE in Germany developed at an HAE LTP Expert Meeting in the year 2024 in Frankfurt, Germany.</p><p><strong>Materials and methods: </strong>A multidisciplinary panel of seven German HAE experts participated in a consensus process to align current guidelines with real-world clinical practice. Following literature review and debate, keynotes were drafted, refined, and voted on. Consensus was defined as ≥ 70% agreement. Key domains included: shared decision-making; flexibility in initiating or adjusting prophylaxis; structured patient education; self-administration; individualized dosing; emergency medication availability; and proactive follow-up, including specific guidance for women of childbearing age.</p><p><strong>Results: </strong>Ten core consensus statements were developed, achieving unanimous (100%, n = 9/10 statements) or strong (≥ 85%, n = 1/10 statements) agreement. It is recommended that the decision to initiate long-term prophylaxis be made through shared decision-making and that the decision made can and should be adjusted again in the further course of treatment. It is advisable to train patients in the technique of self-injection and to start therapy with lanadelumab with a 2-week injection interval in accordance with the product information. The injection interval should be adjusted to the individual patient, and all well-controlled patients should be offered the option of extending the interval without compromising the goal of complete disease control. Even and especially when the prophylaxis is well tolerated, emergency medication must not be neglected.</p><p><strong>Conclusion: </strong>These consensus statements provide a practical, expert-endorsed framework for implementing lanadelumab LTP in clinical practice emphasizing individualized treatment aligned with international guidelines and patient needs.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"10 ","pages":"86-97"},"PeriodicalIF":5.1,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13151902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147871247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding allergy in vitro: Challenges and clinical use of humoral and cellular methods.","authors":"Bettina Wedi, Timo Buhl","doi":"10.5414/ALX02600E","DOIUrl":"10.5414/ALX02600E","url":null,"abstract":"<p><p>In vitro assays are essential tools in diagnosing IgE-mediated allergic diseases and complement clinical history and skin testing across food, inhalant, venom, and drug allergies. This methodological review is intended for clinicians seeking a more detailed understanding of current laboratory-based allergy diagnostics. It summarizes current humoral and cellular diagnostic methods, including total IgE, singleplex and component-resolved specific IgE testing, multiplex IgE platforms, and functional cellular assays such as the basophil activation test and T-cell-based approaches. Humoral assays remain the quantitative foundation of molecular allergy diagnostics, while multiplex arrays broaden diagnostic scope and map sensitization profiles, although platform variability requires cautious interpretation. Cellular assays may add functional information in selected constellations but remain technically demanding, insufficiently standardized, and are best regarded as adjunctive tools in specialized or research settings, with evidence largely derived from selected cohorts. Additional areas - immunotherapy monitoring, mast cell disorders, contact allergy, and oncology - illustrate the broader methodological spectrum of in vitro methods. Persistent unmet needs include harmonization, validated reference standards, and robust interpretive frameworks. Disease-specific applications are discussed in companion articles in this issue.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"10 ","pages":"73-85"},"PeriodicalIF":5.1,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13151904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147871249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prick tests and basophil activation tests in hypersensitivity to SARS-CoV-2 vaccines and components.","authors":"Anna-Emilia Aust, Heidi Reh, Bettina Wedi","doi":"10.5414/ALX02625E","DOIUrl":"10.5414/ALX02625E","url":null,"abstract":"<p><p>In collaboration with certified allergy centers (CACs) in Germany, a standardized procedure was developed for the allergologic evaluation of hypersensitivity reactions to SARS-CoV-2 vaccines. Our CAC prospectively evaluated 60 subjects with prior allergic reactions to SARS-CoV-2 vaccines or components. The investigations included a comprehensive medical history, in-vitro and skin tests. Prick tests were negative in all participants. Two positive basophil activation tests suggested a hypersensitivity to the component polyethylene glycol; however, no clinical relevance was found. Approximately 73% of the subjects reported symptoms during subsequent immunizations, which were milder than the reactions prior to the diagnostic procedures. Most index reactions manifested as non-specific symptoms. The results suggest that subsequent vaccinations following diagnostic procedures were well tolerated, underscoring the importance of careful allergological evaluation prior to vaccination.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"10 ","pages":"63-72"},"PeriodicalIF":5.1,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13151903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147871251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The MRGPRX2 paradigm shift: Redefining mast cell activation pathways in chronic urticaria.","authors":"Kun Wu, Junlin Liu","doi":"10.5414/ALX02618E","DOIUrl":"10.5414/ALX02618E","url":null,"abstract":"<p><p>Chronic urticaria (CU) is a skin disease characterized by recurrent episodes of vascular dilation and increased permeability of the cutaneous and mucosal microvasculature. Although antihistamines and omalizumab remain first-line and second-line therapies, respectively, a significant proportion of patients develop recalcitrant disease phenotypes, highlighting critical unmet needs for innovative therapeutic paradigms. In recent years, emerging insights into Mas-related G protein-coupled receptor X2 (MRGPRX2) have revealed transformative perspectives for elucidating the pathobiology of refractory CU. As a class A G protein-coupled receptor (GPCR) that is predominantly localized to mast cells, MRGPRX2 orchestrates non-IgE-mediated mast cell degranulation through its pluripotent ligand recognition capacity, engaging diverse exogenous cationic compounds, neuropeptides, and certain pharmacological agents. This comprehensive review evaluates recent advancements in deciphering the mechanistic contributions of MRGPRX2 to CU pathogenesis, with the ultimate aim of informing the development of precision diagnostic and therapeutic frameworks for CU management.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"10 ","pages":"52-62"},"PeriodicalIF":5.1,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13123297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of herpes zoster following the first dose of benralizumab.","authors":"Kurtuluş Aksu, Onur Telli, Melis Yağdıran, Fatma Dindar Çelik, Hatice Çelik Tuğlu, Özge Göktürk","doi":"10.5414/ALX400616","DOIUrl":"10.5414/ALX400616","url":null,"abstract":"<p><strong>Introduction: </strong>Biological agents used in the treatment of rheumatic diseases and malignancies cause an increase in herpes zoster susceptibility. This may also be the case for monoclonal antibody treatments used in asthma based on recent pharmacovigilance data.</p><p><strong>Case report: </strong>Herpetic lesions occurred on the anterior chest wall of a 43-year-old patient who was initiated on benralizumab treatment for severe eosinophilic asthma. The patient received diagnosis of herpes zoster and showed significant clinical improvement with oral valacyclovir treatment. Since it was not certain whether the herpes eruption was directly related to benralizumab treatment, benralizumab treatment was continued at the patient's request and with the approval of the dermatology department. The patient did not experience recurrent herpes eruptions or any other clinical problems with the repeated doses given.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"10 ","pages":"49-51"},"PeriodicalIF":5.1,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13096982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing pre- and post-COVID-19 chronic allergy prevalence in children using National Health and Nutrition Examination Survey in 2019 and 2021.","authors":"Bomi Kim, Sunyeob Choi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To investigate changes in demographic characteristics, parental smoking habits, and the prevalence of asthma, atopic dermatitis, and rhinitis among children in South Korea before and after the COVID-19 pandemic.</p><p><strong>Materials and methods: </strong>A retrospective analysis of national health survey data from 2019 and 2021 was conducted, including children aged 3 - 18 years. Factors such as gender, age, location, housing type, family size, income, body mass index, subjective health status, influenza vaccination, family structure, and parental smoking habits were analyzed.</p><p><strong>Results: </strong>No significant differences were found in most demographic characteristics and parental features between 2019 and 2021, except for influenza vaccination rates and mothers' age at first childbirth. The influenza vaccination rate increased from 69.3% in 2019 to 77.8% in 2021, and the average maternal age at first birth increased from 28.46 years to 29.22 years. Asthma diagnoses showed no significant differences between the 2 years after adjusting for general and parent-related characteristics. For atopic dermatitis, significant differences in gender distribution were observed in 2021. Rhinitis diagnoses showed significant differences in age, area, and breastfeeding status between the two years.</p><p><strong>Conclusion: </strong>The COVID-19 pandemic may have influenced certain demographic characteristics, such as influenza vaccination rates and mothers' age at first childbirth, but the prevalence of asthma, atopic dermatitis, and rhinitis among children remained largely unchanged between 2019 and 2021. This study underscores the importance of monitoring the impact of social changes on children's health, particularly during significant events like the COVID-19 pandemic. Further research is required to understand the long-term effects of these changes on child health.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"10 ","pages":"36-48"},"PeriodicalIF":5.1,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13055419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147641127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experts' perspectives on allergic reactions to emerging food sources, pollen and insects.","authors":"Lea Faust, Sabine Dölle-Bierke, Veronika Höfer, Margitta Worm","doi":"10.5414/ALX02611E","DOIUrl":"10.5414/ALX02611E","url":null,"abstract":"<p><p>The rising demand for sustainable diets has led to an increased consumption of alternative protein sources. While ecologically promising, these foods may pose new allergenic risks. We surveyed 127 European allergy experts regarding their clinical perception towards emerging allergenic food sources. Allergic reactions to non-priority allergenic foods were most frequently reported for legumes (83%), followed by hemp (33%), edible insects (21%), and jackfruit (20%). Experts highlighted risks related to cross-reactivity, particularly between edible insects and crustaceans or house dust mites, and between non-priority legumes and peanut, soy, or lupine. Legumes other than peanut, soy, and lupine, as well as edible insects and hempseeds/cannabis, were also rated as most clinically relevant for future practice. Experts also noted rising symptoms due to changes in pollen exposure and insect distribution linked to climate change. Our data underscore the need for the diagnosis of emerging allergenic sources.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"10 ","pages":"28-35"},"PeriodicalIF":5.1,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13010207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality-of-life assessment may support the correct diagnosis of adult wheat allergy.","authors":"Florian Schusta, Anna Neyer, Sabine Dölle-Bierke, Josefine Grünhagen, Veronika Höfer, Margitta Worm","doi":"10.5414/ALX02610E","DOIUrl":"10.5414/ALX02610E","url":null,"abstract":"<p><strong>Background: </strong>Wheat is a frequent cause of food-induced allergic reactions in adults. In this study we aimed to assess the diagnostic value of skin prick test (SPT), specific immunoglobulin E (sIgE), but also quality of life in wheat-sensitized and allergic patients.</p><p><strong>Materials and methods: </strong>In this prospective, clinical study 80 patients were screened for eligibility. Subsequently, 36 wheat-sensitized patients underwent oral food challenges (OFCs) with supraphysiological amounts of gluten at rest and in combination with exercise. The challenge was stopped when objective symptoms occurred. Prior to the challenge, sIgE measurement and a SPT were conducted. The Food Allergy Quality of Life Questionnaire (FAQLQ), Food Allergy Independent Measure (FAIM), and Beck Anxiety Inventory (BAI) were used to assess the quality of life, perceived disease severity, and anxiety of the patients.</p><p><strong>Results: </strong>The OFC was performed with increasing amounts of gluten reaching a supraphysiological level. 24 patients (67%) were OFC positive with 21 reacting at rest. 3 patients reacted after the implementation of exercise. 60% of patients with a self-reported exercise dependency reacted in the OFC at rest. 8 of 21 patients who reacted at rest were rechallenged with exercise and lower doses of gluten, of which 5 reacted again. Exercise lowered the reaction threshold by 50% in these 5 patients. OFC-positive patients had stronger sensitization to gluten and its constituents and showed higher impairment in their quality of life and perceived burden of disease than OFC-negative patients. The receiver operator characteristics model including gluten SPT, omega-5-gliadin sIgE, and the FAIM score to predict OFC positivity yielded a 95.2% sensitivity and 83.3% specificity. Males displayed a higher degree of sensitization, but females had higher FAQLQ and FAIM scores.</p><p><strong>Conclusion: </strong>Although a high rate of exercise dependency was reported, most reactions were elicited at rest when the amount of gluten was upscaled. However, the eliciting amount and reaction threshold was lowered in the presence of exercise. Food allergy-related quality-of-life data can indicate psychological impairment due to the disease but may also serve as a patient-reported outcome tool which can support the diagnostic accuracy of wheat allergy.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"10 ","pages":"16-27"},"PeriodicalIF":5.1,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12980459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147464675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Achieving a normal life in hereditary angioedema: Quality of life and treatment gaps among German HAE patients.","authors":"Markus Magerl, Thomas Buttgereit, Inmaculada Martinez-Saguer, Petra Staubach-Renz, Jens Greve, Emel Aygören-Pürsün, Lucia Schauf, Kathrin Schön","doi":"10.5414/ALX02603E","DOIUrl":"10.5414/ALX02603E","url":null,"abstract":"<p><strong>Background: </strong>Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent swelling attacks. Current guidelines for HAE management emphasize achieving complete disease control to normalize patients' lives. Quality of life (QoL) differences between patients with 0 attacks and those with persistent attacks remain to be explored.</p><p><strong>Materials and methods: </strong>The German patient organization for individuals affected by hereditary angioedema, HAE Vereinigung e.V. conducted an online survey with 122 HAE patients in Germany in 2024. Participants were categorized according to their therapy - long-term prophylaxis (LTP) or on-demand therapy (ODT) - and according to their attack frequency over the last 6 months. Patient-reported outcomes for functional, emotional, and social impacts were analyzed to evaluate QoL.</p><p><strong>Results: </strong>Although 83% of patients expressed satisfaction with their treatment, 59% of patients still had attacks. Patients on LTP reported significantly fewer attacks (p < 0.001) and higher QoL compared to those on ODT (p < 0.001). Patients with 0 attacks consistently showed significantly better outcomes across all QoL domains than those with 1 or more attacks (p < 0.001).</p><p><strong>Conclusion: </strong>The findings highlight that even minimal residual disease activity can meaningfully reduce QoL. Achieving complete attack freedom, rather than partial control, is necessary to restore normalcy for patients with HAE. Hence, regular adjustments of the HAE management plans based on patient-reported outcomes are crucial to ensure that treatment strategies address both medical and QoL needs.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"10 ","pages":"1-10"},"PeriodicalIF":5.1,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12958277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147367985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}